Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. company information, Employees & Contact Information

At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.

Company Details

Employees
130
Address
100 Marine Pkwy,
Phone
(650) 213-8444
Email
in****@****no.life
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Redwood City, California
Looking for a particular Soleno Therapeutics, Inc. employee's phone or email?

Soleno Therapeutics, Inc. Questions

News

Soleno Therapeutics to Participate in Upcoming November Conferences - GlobeNewswire

Soleno Therapeutics to Participate in Upcoming November Conferences GlobeNewswire

Soleno Therapeutics (NASDAQ: SLNO) sets November talks at Guggenheim and Jefferies - Stock Titan

Soleno Therapeutics (NASDAQ: SLNO) sets November talks at Guggenheim and Jefferies Stock Titan

Soleno Therapeutics, Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 - Quiver Quantitative

Soleno Therapeutics, Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 Quiver Quantitative

Soleno Therapeutics, Inc. Securities Lawsuit Investigation - Claim Depot

Soleno Therapeutics, Inc. Securities Lawsuit Investigation Claim Depot

Soleno Therapeutics' 'life-changing' rare-disease drug approved | STAT - statnews.com

Soleno Therapeutics' 'life-changing' rare-disease drug approved | STAT statnews.com

Soleno Therapeutics (NASDAQ: SLNO) to report third-quarter results Nov 4 at 4:30 PM ET - Stock Titan

Soleno Therapeutics (NASDAQ: SLNO) to report third-quarter results Nov 4 at 4:30 PM ET Stock Titan

Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025 - Quiver Quantitative

Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025 Quiver Quantitative

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET - GlobeNewswire

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET GlobeNewswire

Nearly 30 Years of CFO Experience: Soleno Adds Mark W. Hahn to Board to Support VYKAT XR Launch - Stock Titan

Nearly 30 Years of CFO Experience: Soleno Adds Mark W. Hahn to Board to Support VYKAT XR Launch Stock Titan

Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors - GlobeNewswire

Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors GlobeNewswire

Rare Disease Biotech Soleno Sets Q2 Earnings Date: Key Updates on PWS Treatment Expected - Stock Titan

Rare Disease Biotech Soleno Sets Q2 Earnings Date: Key Updates on PWS Treatment Expected Stock Titan

Rare Disease Biotech Soleno Therapeutics Lines Up 5 Major Wall Street Healthcare Conference Presentations - Stock Titan

Rare Disease Biotech Soleno Therapeutics Lines Up 5 Major Wall Street Healthcare Conference Presentations Stock Titan

Soleno Therapeutics to Participate in Upcoming September Conferences - GlobeNewswire

Soleno Therapeutics to Participate in Upcoming September Conferences GlobeNewswire

Soleno Reports First Revenue Quarter: VYKAT XR Launch Draws 295 Prescribers in 90 Days - Stock Titan

Soleno Reports First Revenue Quarter: VYKAT XR Launch Draws 295 Prescribers in 90 Days Stock Titan

Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire

Soleno Therapeutics Provides Update on U.S. Launch of GlobeNewswire

Soleno Therapeutics Announces Multiple Presentations at the - GlobeNewswire

Soleno Therapeutics Announces Multiple Presentations at the GlobeNewswire

Soleno Therapeutics Announces Preliminary Financial and - GlobeNewswire

Soleno Therapeutics Announces Preliminary Financial and GlobeNewswire

Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome - GlobeNewswire

Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome GlobeNewswire

Soleno Therapeutics’ ‘life-changing’ drug nears approval decision - statnews.com

Soleno Therapeutics’ ‘life-changing’ drug nears approval decision statnews.com

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 GlobeNewswire

Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire

Soleno Therapeutics Provides Update on U.S. Launch of GlobeNewswire

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - GlobeNewswire

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome GlobeNewswire

Soleno Therapeutics Announces VYKAT(TM) XR Launch - GlobeNewswire

Soleno Therapeutics Announces VYKAT(TM) XR Launch GlobeNewswire

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results GlobeNewswire

Breakthrough: First FDA-Approved Drug for Prader-Willi Syndrome Hunger Management - Stock Titan

Breakthrough: First FDA-Approved Drug for Prader-Willi Syndrome Hunger Management Stock Titan

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - Yahoo Finance

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC Yahoo Finance

Angela Soleno Obituary (1980 - 2025) - Santa Maria, CA - Lompoc Record - Legacy obituary

Angela Soleno Obituary (1980 - 2025) - Santa Maria, CA - Lompoc Record Legacy obituary

Soleno Therapeutics Announces FDA Extension of Review - GlobeNewswire

Soleno Therapeutics Announces FDA Extension of Review GlobeNewswire

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock GlobeNewswire

Soleno Therapeutics Announces Pricing of Approximately $120 - GlobeNewswire

Soleno Therapeutics Announces Pricing of Approximately $120 GlobeNewswire

Soleno Therapeutics Announces Positive Statistically - GlobeNewswire

Soleno Therapeutics Announces Positive Statistically GlobeNewswire

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results - GlobeNewswire

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results GlobeNewswire

Top Soleno Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant